30
Revenue growth was driven by the rapid expansion of its whole exome and genome business, which grew over 125% year-over-year and now accounts for 74% of total revenue. This segment is the company’s crown jewel and the primary focus of investor interest.
The second-quarter loss was lower than expected, as GeneDx moves towards profitability, which it anticipates by 2025.
The company reduced its quarterly cash burn to $6.1 million, down over 65% from $17.2 million in Q1, marking its ninth consecutive quarter of improvement. At the end of Q2,…